This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The generation of an effective AIDS vaccine is greatly complicated by our incomplete knowledge of the correlates of immune protection during HIV infection. Clinical and pre-clinical immunogenicity studies indicate that replication-defective adenovirus (Ad) vectors based can robustly induce strong and persistent immune responses to HIV/SIV antigens. This project focuses on the immunogenicity and protection from SIV challenge conferred by chimpanzee adenovirus (AdC)- based candidate AIDS vaccines. Over the past year we made significant progress in our in vivo studies of AdC-based candidate vaccines in rhesus macaques (RMs). In this study, 10 animals received AdC6/AdC7;10 received AdC7/AdC6, and 10 are unvaccinated controls. Please note that, given the long schedule of vector administration, which calls for a six-month resting period after each immunization, the animals will be challenged in February and again in June.
Showing the most recent 10 out of 912 publications